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A B S T R A C T
Purpose
Preventive health strategies for women at increased hereditary risk of ovarian cancer include
gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement
therapy (HRT) is often prescribed to compensate for postsurgical endocrine deficiencies. This
study examined the impact of HRT use on levels of endocrine symptoms and sexual functioning
among premenopausal women who have undergone PBSO. Comparisons were made with similar
women undergoing GS.
Patients and Methods
Questionnaire data on endocrine symptoms and sexual functioning were obtained from 450
premenopausal, high-risk women who had participated in this nationwide, cross-sectional,
observational study.
Results
Thirty-six percent of women had undergone PBSO and 64% had opted for GS. In the PBSO group,
47% of the women were current HRT users. They reported significantly fewer vasomotor
symptoms than nonusers (P .05). However, compared with premenopausal women undergoing
GS, oophorectomized HRT users were more likely to report vasomotor symptoms (P  .01). HRT
users and nonusers reported comparable levels of sexual functioning. Compared with women in
the GS group, oophorectomized HRT users reported significantly more sexual discomfort due to
vaginal dryness and dyspareunia (P  .01).
Conclusion
Although HRT has a positive impact on surgically induced vasomotor symptoms, it may be less
effective than is often assumed. Symptom levels remain well above those of premenopausal
women undergoing screening, and sexual discomfort is not alleviated by HRT. Physicians need to
provide younger high-risk women considering PBSOwith realistic information about both benefits and
drawbacks of this preventive strategy, including information about premature menopause and HRT.
J Clin Oncol 24:3576-3582. © 2006 by American Society of Clinical Oncology
INTRODUCTION
Preventivehealthcarerecommendationsforwomenat
increased hereditary risk of ovarian cancer include pe-
riodic gynecologic screening (GS) and/or prophylactic
bilateral salpingo-oophorectomy (PBSO). In the
face of uncertain efficacy of the currently available
screening techniques, including transvaginal ul-
trasonography and CA-125 serology,1 and the es-
tablished risk-reducing benefit of PBSO for
ovarian and breast cancers,2,3 carriers of BRCA1/
BRCA2 gene mutations are usually advised to un-
dergo PBSO after the age of 35 years or after the
completion of childbearing.4
Adverse effects associated with PBSO in pre-
menopausal women include loss of fertility, imme-
diate onset of menopause with vasomotor and
urogenital symptoms,5,6 and a decline in sexual
interest and activity.7 The management of surgi-
cally induced menopause requires strategies for
alleviating the climacteric symptoms, and im-
proving women’s functioning and quality of life.
Hormone-replacement therapy (HRT) is often
prescribed at the time of surgery.8
HRThas proven to be highly effective in allevi-
ating vasomotor symptoms (eg, hot flushes, sweats)
and urogenital atrophy in women undergoing
natural menopause.8,9 Because of its androgenic
properties, tibolone has shown to have additional
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beneficial effects on sexual functioning.10-12 Recent studies,13-17
however, indicate that HRT use by healthy menopausal women is
associated with increased risks of breast cancer and cardiovascular
complications, and that these risks may overshadow the potentially
beneficial effects on osteoporosis and colon cancer. Current rec-
ommendations call for short-duration HRT treatment for severe
symptoms, and avoidance of long-term use for prevention of
chronic health conditions.18,19
Only two studies have investigated post-PBSO menopausal
symptoms and sexual functioning as part of a larger investigation of
the psychosocial impact of prophylactic surgery.20,21 In both studies,
PBSOwas found to be associated with the occurrence of menopausal
symptoms. The results with regard to sexual functioning were incon-
sistent,with some evidence of sexual impairment in the studyof Elit et
al,20 but not in the study of Fry et al.21 Neither of these studies inves-
tigated endocrine symptoms and sexual functioning explicitly in rela-
tion to post-PBSOHRT use.
The primary focus of this report is on the impact of HRT use on
the levels of endocrine symptoms and sexual functioning among pre-
menopausal women who have undergone PBSO. Comparisons are
made with premenopausal high-risk women undergoing GS.
PATIENTS AND METHODS
Participants and Procedures
This investigation was part of a larger, cross-sectional, observational
study of psychosocial issues surrounding ovarian cancer prevention among
high-risk women in the Netherlands. Study participants were recruited from
the gynecology departments of eight hospitals. Women were eligible for the
larger study if theywerebetween30and75yearsof age, came fromahereditary
breast/ovariancancer family, andhadsoughtgynecologic adviceonpreventive
measures at one of the clinics between 1996 and 2001. Patients were excluded
from participation if they had undergone oophorectomy as treatment for a
medical condition, or hadmetastatic cancer or any other severe comorbidity.
Thecurrentanalysiswas restricted todataofwomenwhowerepremenopausal
at the time of PBSO or were currently premenopausal (GS group). Premeno-
pausewas defined as having regularmenses during the last 6months or before
PBSO.Aftersurgery,womenwereprescribedstandarddosesofHRT(estrogen/
progesterone or tibolone) administered either orally or transdermally.
Eligible women who had undergone PBSO or GS received an invitation
letter bymail, an informed consent form, a questionnaire, and a postage-paid
return envelope. If no response was received after 2 weeks, reminders bymail
and telephone were used. Patients were classified as nonrespondents if they
actively declined to participate, or if they could not be reached after multiple
attempts. The study was approved by the institutional review boards of all
participating hospitals.
Measures
The 18-item Functional Assessment of Cancer Therapy–Endocrine
Symptoms (FACT-ES) was used to assess menopausal symptoms.22 Oc-
currence of each symptom in the last 4 weeks is scored on a 5-point
Likert-type scale, ranging from “not at all” to “verymuch.” Item scores can
be summed to obtain a scale score (range, 0 to 72), with lower values
indicating more symptoms.
The Sexual Activity Questionnaire23 was used to measure sexual func-
tioning. It consists of three scales: pleasure (six items on desire, enjoyment,
satisfaction, and current frequency of activities); discomfort (two items on
vaginal dryness, pain and discomfort during penetration); and habit (fre-
quency of sexual activity compared with the usual level). Lower scores repre-
sent poorer sexual functioning.
Medical and Sociodemographic Data
HRTusewas determined on the basis of patient’s self-report, confirmed
by medical record audit. Sociodemographic and other medical data were
obtained from thequestionnaire and themedical records. These data included
age, marital status, education, employment, menstrual and reproductive his-
tory, personal history of cancer and its treatments, DNA status, prevalence of
breast/ovarian cancer among relatives, andprophylactic surgery. In the case of
discrepancies between self-reported and medical record data, the latter were
considered as the primary information source.
Statistical Analysis
Descriptive statistics were generated to characterize the sample in terms
of sociodemographic andmedical variables. Student’s t tests and 2 tests were
used to examine potential differences in the background characteristics of
women who had undergone PBSO versus GS.
The study sample was divided into three groups according to the type of
prevention and the current hormonal status: oophorectomized, current users
and nonusers of HRT (PBSO HRT users and PBSO HRT nonusers), and
premenopausal women undergoing GS. One-way analysis of covariance was
used to test for groupdifferences in endocrine symptoms and sexual function-
ing, controlling for possible confounders (age, DNA status, history of
breast cancer, tamoxifen use, and prophylactic mastectomy). AmongHRT
users, the effect of the type of medication (estrogen/progesterone v tibo-
lone) was also investigated.
In addition, individual symptoms of the FACT-ES scale were dichot-
omized (symptom present was considered to be a response in either of the
two highest categories, “verymuch” and “quite a bit”). For each symptom,
a multivariate logistic regression analysis was conducted to determine




Of 1,205 high-riskwomen in the hospitals’ databases, 1,084were
eligible for study participation (Fig 1). The reasons for ineligibility
were oophorectomy carried out as treatment for a medical condition
(n  94), death (n  23), metastatic cancer (n  3), and severe
psychiatric problems (n  1). In total, 858 (79%) women returned
completed questionnaires. Lack of interest (n  137), poor health
(n 8), and emotional problems (n 8) were the main reasons for
nonparticipation. The data of 12 women had to be excluded: five
women reported that the questionnaire was not applicable to their
present situation, given that their cancer risk was found not to be
increased based on DNA testing; five women had a high percentage
( 50%) of missing values; and two women had undergone an oo-
phorectomy before 1996. Therewere no statistically significant differ-
ences between the respondents and nonrespondents in the type of
ovarian cancer prevention and mean age (data not shown). Among
the respondents, 450 premenopausal women were identified, of
whom 164 (36%) had undergone PBSO. Data on menopausal status
of nonrespondents were not available.
The background characteristics of the sample are shown in
Table 1. Compared with the GS group, the PBSO group was signifi-
cantly older,more likely to have been diagnosedwith breast cancer, to
be BRCA1/2 mutation carriers, and to have undergone prophylactic
mastectomy (all P  .001). At the time of assessment, 47% of the
PBSOgroup reported current use ofHRT,with the largest percentage
taking estrogen/progesterone medications. HRT users were younger
(45 v 47 years; P .05) and had undergone PBSO at a younger age
(41 v 44 years; P  .01), were less likely to have a history of breast
PBSO, Menopausal Symptoms, and HRT
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cancer (17% v 47%; P .001), and were more likely to have under-
gone prophylactic mastectomy (62% v 41%; P .01) than nonusers.
One fourthof the latter groupreportedhavingusedHRTat some time
postsurgery. Data on the reasons for HRT discontinuation were not
available. Themajority of current HRT users (82%) received a prescrip-
tion for HRT at the time of PBSO, and reported having started HRT
directly after surgery (72%) and being (highly) compliant withHRTuse
(99%;Table 1).
Endocrine Symptoms
Table 2 presents themeanFACT-ES scale scores and the individ-
ual symptom frequencies. As indicated by themean scores, the PBSO
HRT users group reported significantly fewer symptoms overall than
thePBSOHRTnonusers group (P .05).At the individual endocrine
symptom level, significant between-group differences were found
only for hot flushes, and cold and night sweats (all P .05).
The PBSO HRT users group reported significantly more endo-
crine symptoms overall (FACT-ES scale scores) than the GS group
(P .05). Significant groupdifferenceswere found in the frequencyof
all vasomotor symptoms, vaginal dryness, pain/discomfort during
intercourse, and loss of interest in sex, with the PBSO HRT users
group experiencingmore problems (all P .01).
Sexual Functioning
The majority of all study participants reported being sexually
active (Table 3), and no significant differences between the groups
were observed, after controlling for age, history of breast cancer, ta-
moxifen use, and prophylactic mastectomy. “Lack of interest in sex”
or “having a bodily problem” were the most common reasons re-
ported by oophorectomized women for not being sexually active
(44% to 78%). Thirty-three percent of premenopausal women in the
GS group reported being too tired or their partner being too tired as the
main reason for their sexual inactivity (data not shown in the table).
ThePBSOHRTusers andPBSOHRTnonusers groups reported
comparable levels of sexual functioning, as measured by the pleasure,
discomfort, and habit scales of the Sexual Activity Questionnaire.
Compared with the GS group, the PBSO HRT users group reported
significantly more discomfort during sexual activities (P .01).
Although the numbers were small (Table 1), we examined
whether the type of HRT used differentially affected levels of endo-
crine symptoms and sexual functioning. No statistically significant
differences were found between those who used estrogen/progester-
one versus tibolone (data not shown in the table).
DISCUSSION
Manywomen fromhereditarybreast/ovarian cancer families consider
PBSO or GS as a strategy for managing their increased risk of devel-
oping ovarian cancer. Although the risk reduction attributed to PBSO
is largest in premenopausal women,2,3,24 the resulting postoperative
endocrine imbalance may affect functioning in several health do-
mains. This report presents the results of a study that investigated the
impact of PBSO on endocrine symptoms and sexuality among pre-
menopausal, high-risk women, and the effect of HRT in alleviating
these symptoms.
In theNetherlands,HRT is recommended as ameans of alleviat-
ingvasomotorandsexual symptomsonly tohigh-riskwomenwhoare
premenopausal at the timeof surgery. Inclinicalpractice, it is generally
recommended that HRT use begin immediately after PBSO, and be
discontinued at the time of expected natural menopause (ie, at ap-
proximately 50 years of age).4 There is currently no consensus about
whether HRT use after oophorectomy contributes additionally to the
already increased risk of breast cancer resulting from BRCA1 or
Fig 1. Study participant flow. QOL, quality of life.
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BRCA2mutation carriership.25 Recent studies4,26 have suggested that
decisions regarding HRT use should be based on quality-of-life con-
siderations, rather than on life expectancy. Moreover, short-term
HRTuse does not negate the protective effect of PBSOon subsequent
breast cancer risk in BRCA1/2mutation carriers.26
When deciding to undergo PBSO, younger women may expect
that postsurgicalHRTusewillminimize if not entirely preventmeno-
pausal symptoms, and that their functioning will return approxi-
mately to the presurgery level. In our study, 47%of oophorectomized
women were currently using HRT. The results indicated that current





















Mean 46 45 47 41
SD 6 5 7 6 .000; .048†; .000‡
Range 34-59 34-51 34-59 30-54
Marital status .892; .315†; .409‡
Married/cohabitating 139 85 68 88 71 83 243 85
Unmarried/without partner 25 15 9 12 16 17 43 15
Education level .087; .278†; .719‡
Primary school/lower
level high school
30 18 11 13 19 22 34 12
Middle level high school 85 52 41 53 44 51 138 48
Advanced vocational/university 49 30 25 34 24 27 114 40
Parity .006; .443†; .110‡
Nulliparous 22 13 12 16 10 11 69 24
Primi-or multiparous 142 87 65 84 77 89 217 76
DNA status .000; .135†; .000‡
BRCA 1/2 carrier 128 78 61 79 67 77 89 31
Nonconclusive 16 10 4 5 12 14 51 18
Not tested/other 20 12 12 16 8 9 146 51
History of breast cancer 54 33 13 17 41 47 57 20 .000; .000†;.547‡
Current use of tamoxifen 3 2 0 0 3 3 3 1 .359; .100†; .462‡
Previous hysterectomy 7 5 4 5 3 3 1 0 .019; .360†; .006‡
Prophylactic mastectomy 84 51 48 62 36 41 49 17 .000; .007†; .000‡
Age at PBSO, years
Mean 43 41 44 —
SD 6 5 6 .004†
Time since PBSO, years
Mean 2.8 3.1 2.5 —
SD 2.2 2.3 2.1 .111†
Ever use of HRT 99 60 77 100 22 25 — —
Current use of HRT 77 47 77 100 — — —
Type of HRT currently used —
Estrogen/progesterone — 54 70 — —
Tibolone — 23 30 — —
Duration of HRT use in current
users, years§
— — — —
Mean 3.0
SD 2.3
HRT prescribed at the time of
PBSO
— 63 82 — — —
HRT use started directly after PBSO — 55 72 — — —
HRT used as prescribed —
Always — 69 90 — —
Most of the time — 7 9 — —
Abbreviations: PBSO, prophylactic bilateral salpingo-oophorectomy; HRT, hormone-replacement therapy; GS, gynecologic screening; SD, standard deviation.
Total PBSO group v GS group.
†PBSO HRT users group v PBSO HRT nonusers group.
‡PBSO HRT users group v GS group.
§Time interval between first postsurgical HRT use and current HRT use at the time of questionnaire assessment.
Self-reported data.
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HRTuse significantly reduced vasomotor symptoms,with prevalence
rates being 14% to 21% lower among HRT users versus nonusers.
Although these reductions are not trivial, previous studies ofHRTuse
among women experiencing natural menopause have demonstrated
larger reductions in vasomotor symptoms.9 In addition, contrary to
expectations based on clinical experience, no significant differences in
the frequencyofother endocrine symptoms (eg, vaginal dryness)were
observed between HRT users and nonusers after controlling for pos-
sible confounders and type of medication. Surgical menopause may
entail symptoms of higher severity forwhich commonly appliedHRT
may be less effective, given that it was originally designed to compen-
sate for gradual endocrine losses in naturally menopausal women.
This issue, however, needs to be addressed empirically.
Although HRT use does have a salutary effect on vasomotor
symptoms in women with surgically inducedmenopause, it does not
alleviate these symptoms entirely, as evidenced by the comparison


















Mean 58.0 54.6 61.7
SD 10.9 9.7 9.8
Prevalence of selected symptoms
Hot flushes 15 20 36 41 6 2 .004§;.000
Cold sweats 18 23 33 38 6 2 .034§;.000
Night sweats 19 25 34 39 20 7 .037§;.001
Vaginal discharge 4 5 1 1 26 9 .176§;.309
Vaginal itching/irritation 4 5 5 6 11 4 .865§;.445
Vaginal bleeding 3 4 1 1 26 9 .283§;.107
Vaginal dryness 10 13 21 24 6 2 .152§;.002
Pain/discomfort with intercourse 9 12 15 17 9 3 .133§;.008
Lost interest in sex 12 16 19 22 11 4 .350§;.002
Gained weight 13 17 16 18 26 9 .777§;.106
Lightheaded/dizzy 3 4 5 6 11 4 .585§;.610
Vomited 8 1 1 1 0 0 .959§;.994
Diarrhea 8 1 1 1 3 1 .508§;.516
Headaches 10 13 9 10 34 12 .617§;.826
Feel bloated 5 6 7 8 20 7 .673§;.480
Breast sensitivity/tenderness 2 2 4 5 23 8 .226§;.080
Mood swings 9 12 17 20 31 11 .174§;.955
Irritable 6 8 13 15 23 8 .160§;.726
Abbreviations: PBSO, prophylactic bilateral salpingo-oophorectomy; HRT, hormone-replacement therapy; GS, gynecologic screening; SD, standard deviation.
Unadjusted percentages.
†All analyses were adjusted for age, history of breast cancer, tamoxifen use, and prophylactic mastectomy.
‡Possible score range: 0-72. Lower scores indicate more symptoms.
§PBSO HRT user v PBSO HRT nonuser.
PBSO HRT user v GS.










PMean SD Mean SD Mean SD
Sexually active women, % 83 77 86 .713†; .693‡
SAQ scale scores§
Pleasure 10.2 3.2 9.8 3.6 11.2 2.8 .700†; .154‡
Discomfort 4.8 1.5 4.4 1.7 5.5 1.0 .166†; .003‡
Habit 1.0 0.5 0.9 0.6 0.9 0.5 .451†; .713‡
Abbreviations: PBSO, prophylactic bilateral salpingo-oophorectomy; HRT, hormone-replacement therapy; GS, gynecologic screening; SD, standard deviation.
All analyses were adjusted for age, history of breast cancer, tamoxifen use and prophylactic mastectomy. P values apply to the following comparisons:
†PBSO HRT users v PBSO HRT nonusers.
‡PBSO HRT users v GS.
§Scores available only for sexually active women. Lower scores indicate poorer sexual functioning.
Madalinska et al
3580 JOURNAL OF CLINICAL ONCOLOGY
131.174.209.229
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on July 11, 2012 from
Copyright © 2006 American Society of Clinical Oncology. All rights reserved.
withpremenopausalwomenundergoingGS. It is commonlyassumed
that HRT use will virtually eliminate hot flushes.27 The current find-
ings indicate that oophorectomized HRT users continue to report
significantlymorevasomotorandotherendocrine symptomsthanthe
group of premenopausal women undergoing screening. The only
previous study21 that has compared the physical and psychosocial
functioning of women undergoing PBSO versus GS found an overall
trend for the surgical group (n  29) to report more menopausal
symptoms than thenonsurgical group(n28).However, it isunclear
if that study adjusted statistically for currentHRTuse. In addition, the
observed group differences were with regard to aches and pains,
weight gain, andmenstrual problems, but not vasomotor symptoms.
The majority of women in the current study reported being
sexually active, andno significantdifferenceswere found in the level of
activity between the oophorectomized HRT users, oophorectomized
HRT nonusers, andwomen undergoing screening. However, oopho-
rectomizedwomenwhowere not sexually active attributed their inac-
tivity significantly more frequently to decreased libido and bodily
problems than did women in the screening group. HRT users and
nonusers reported similar levels of sexual functioning, andHRTusers
reported significantlymorediscomfort (eg, vaginaldryness, dyspareu-
nia) than women undergoing screening. These results are in line with
other studies6,20,28,29 that have reported impairments in sexual func-
tioningdue to surgically inducedmenopause, and sustainedproblems
with libido, lubrication, and dyspareunia despite HRT use.6,28 How-
ever, these studies included amore heterogeneous sample of women,
including thosewhohadundergoneoophorectomyasamedical treat-
ment. Two other studies of high-risk women who had undergone
PBSO have reported that HRT may mitigate potential sexual prob-
lems.21,30 However, these were single-center studies, the results of
which were based on (qualitative) data derived from small samples.
Decreased androgen concentrations after PBSO may underlie
sexualproblems.31 Somestudieshave reported thatuseof transdermal
testosterone32 or tibolone improves sexual function.10,12,33 In our
sample,noneof thewomenwere treatedwith testosterone.Wedidnot
observe any significant differences in sexual functioning among
women using tibolone versus estrogen/progesterone. However, the
sample size for this specific comparison was limited, with small num-
bers of tibolone users.
The strength of our study lies in its multicenter design, the large
sample size, and the high response rate. We believe that the study
sample is representative of high-risk women in the Netherlands. The
main limitation of the study is its cross-sectional design, which does
not allow for interpretation of causal relationships or detection of
changes in endocrine symptom levels or sexual functioning over time
due to the absence of a baseline (ie, presurgical) assessment. We are
currently conducting a prospective, multicenter study with presurgi-
cal and follow-up assessment.
In addition, although we controlled for possible confounders in
our statistical analyses, statistical adjustments cannot entirely rule out
the possibility of indication bias, given that the study design was
nonrandomized. Indication bias would suggest that the severity of
menopausal symptoms would be decisive in whether or not to use
HRT following PBSO. In clinical practice, the gynecologists from the
participating hospitals typically prescribe standard doses of HRT pre-
operatively andrecommend thatwomencommenceHRTusedirectly
after PBSO, rather than waiting until menopausal symptoms occur.
The majority of HRT users in our sample began using HRT directly
after PBSO, and theywere highly compliantwith its use.Nevertheless,
there are several reasonswhyone cannot entirely rule out the possibil-
ity of indication bias. First, for those women who were current HRT
users, no information was available on whether their use had been
continuousor intermittentduring theperiodafter surgery.Second,no
data were available about the reasons why some women had discon-
tinued postsurgical use of HRT.We would emphasize, however, that
although indicationbiasmayplay some role in the comparisonsmade
betweenHRTusers andnonusers, it does notwhen comparing symp-
toms of oophorectomizedHRT users with those of women undergo-
ing gynecologic screening. Ultimately, one would want to investigate
these issues in a randomized clinical trial. However, the feasibility of
such a randomized clinical trial is questionable because it is likely that
many eligible women would not want to be randomly assigned to
HRT use or nonuse, or to a placebo group.
In conclusion, this study has documented relatively high levels of
endocrine symptomsand impaired sexual functioningassociatedwith
PBSO. Although the efficacy of HRT in alleviating symptoms of nat-
ural menopause has been established in numerous randomized stud-
ies, ourobservationaldata suggest thatHRTmaybe less effective in the
case of surgically induced symptoms. Randomized studies are needed
todetermine the efficacyofHRTand testosterone supplementation in
alleviating menopausal symptoms after PBSO, including dose-
response issues. In addition, the role of nonhormonal medical treat-
ments and psychosocial interventions in alleviating climacteric
complaints merits further study. Ganz et al34 have demonstrated that
psychosocial interventions in combination with nonhormonal medi-
cations are a viable alternative to HRT among older breast cancer
survivors suffering from menopausal symptoms. Possibly, younger
oophorectomized womenmay also benefit from such interventions.
Physicians need to provide younger high-risk women consider-
ing PBSO with realistic and balanced information about both the
benefits and possible drawbacks of this preventive strategy, including
information about ovarian function, menopause, HRT, and psycho-
social effects (eg, reduced cancer worries and lower risk percep-
tions).30,35,36 Such balanced information will help women in making
informed decisions about the optimal preventive health strategy.
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